Recordati consensus picture for 2026, analysts stay constructive on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:55.

Recordati (IT0003828271) sits in the Italian pharmaceutical sector with its shares listed on Borsa Italiana in Milan. For 2026, the group trades against a documented analyst consensus on earnings and valuation published by several European brokers according to MarketScreener.

What analysts currently say

Recordati is covered by a cluster of brokers including HSBC, Jefferies and Mediobanca, with most houses rating the stock at Buy or Hold as compiled by MarketScreener. The consensus 12-month price target centers around 50 euros per share, implying a modest upside against recent Milan trading levels according to the same source.

On the earnings side, the compiled estimates point to mid-single-digit sales growth for 2026 and an adjusted EBITDA margin above 30 percent, in line with Recordati’s historical profitability profile according to consensus data. The group’s valuation multiple around 18-20 times expected 2026 earnings places it broadly in line with peers such as Grifols and Almirall in the European specialty pharma segment per MarketScreener comparisons.

How the stock trades in Milan

Recordati shares trade on Borsa Italiana and are part of the FTSE MIB index, which anchors the stock in the Italian blue-chip universe according to Borsa Italiana information. The shares have shown relatively muted volatility in recent months, with a 52-week range documented between roughly 40 and 55 euros and an average daily volume in the low hundreds of thousands of shares as compiled by MarketWatch.

Technical chart data from TradingView place Recordati trading around its 200-day line near the 48-euro level in June 2026, suggesting a broadly sideways trend over the medium term. The beta versus the FTSE MIB remains below 1, indicating the stock has moved less than the wider Italian equity market over the past year according to TradingView estimates.

The products behind the earnings

Recordati generates most of its revenue from prescription pharmaceuticals in cardiovascular, urology and rare disease indications, with well-known brands including Zanidip for hypertension and Livazo for hypercholesterolemia according to the company’s 2024 annual report. The rare disease portfolio includes treatments for urea cycle disorders and other metabolic conditions, sold globally through a specialty distribution network per Recordati’s investor presentations.

Where the shares trade today

Recordati shares (IT0003828271) trade on Borsa Italiana in Milan at around 48 euros as of 2026-06-23, 11:30, based on recent price data from Borsa Italiana.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but may be subject to change.